|
A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT). |
|
|
Consulting or Advisory Role - Bayer; Dendreon; Ferring; Janssen Scientific Affairs; Medivation/Astellas; Sanofi; Takeda; Tolmar |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma |
Speakers' Bureau - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Baxter (I) |
Research Funding - Astellas Pharma |
|
|
Consulting or Advisory Role - Medline Industries |
|
|
No Relationships to Disclose |
|
|
Employment - Medivation; Pfizer |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Ferring; Hybridyne Imaging Technologies; Janssen; Sanofi |
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |
Research Funding - Astellas Pharma; Bavarian Nordic; Bayer; Ferring; Janssen; Medivation; Nucleix; Progenics; Sanofi; Spectracure |